SFJ backs Asian studies of Pfizer cancer drug; Aravis to buy AGI in $8M deal;

 @FierceBiotech: GSK, Theravance will file for approval of lung drug Relovair despite mixed batch of clinical data. Article | Follow@FierceBiotech

 @JohnCFierce: Big biotech buyouts are fine, but I'd prefer a hot IPO market any day. And what are the chances of that this year? Article | Follow @JohnCFierce

 @MarkHFierce: Two overexpressed genes + excess MeCP2 protein = anxious mice. Maybe someday this could help some anxious people. Story | Follow @MarkHFierce

 @MaureenFierce: Greenpeace activist leading project to reduce vaccine spoilage in emerging markets using solar-powered coolers, fridges. Story | Follow @MaureenFierce

> Aravis Therapeutics has struck a deal to buy Ireland's AGI Therapeutics for $8.4 million. Story

> Venture-backed SFJ Pharmaceuticals is providing funding and late-stage clinical support for Asian studies of Pfizer's kidney cancer drug axitinib. Story

> Norway's BerGenBio, a cancer drug developer, has completed an $8.8 million Series A financing round. The financing will be used primarily to take lead compound BGB324 into clinical trials and to develop a companion diagnostic. Lead investors are Sarsia Seed AS and Investinor AS. Release

> On Friday, Rockville, MD-based Supernus announced that it had raised $42 million to support the development and commercialization of CNS treatments. Release

> Canada's Cangene plans to cut 120 jobs, or 17% of its workforce. Story

 @FiercePharma: Apparently BMS' strategy guy went out with a bang: $2.5B deal for hep C developer Inhibitex. News | Follow@FiercePharma

> Valeant targets $200M in post-merger cost cuts. Article

> Novartis pulls OTC meds made at troubled plant. News

Biotech IT News

> Knome taps Pfizer vet as new CEO. Article

> Accelrys CEO hints at more buyouts after VelQuest acquisition. News

> Bristol-Myers Squibb outsources network duties to British Telecom. Story

> Quintiles starts digital unit in online hunt for study patients. More

> New software aids RNA cocktail against cancer. Item

Medical Device News

> Philips sues Zoll alleging infringement of patents covering defibrillators. Item

> Ventana inks separate companion Dx deals. More

> FDA: J&J, others must study safety of vaginal mesh. Story

> Cook to invest $21M in Ireland, eyes India for expansion. Article

And Finally... Researchers at TGen have been mapping mutations and cellular pathway changes that spur lung cancer in people who have never smoked. Release

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.